Liver imaging with
gadolinium contrast enhanced MRI is sometimes not sufficient for a reliable diagnosis of
liver lesions.
For this reasons, special
liver Contrast agents that are targeted to the reticuloendothelial system (RES), have been developed to improve both detection and characterization of
liver and spleen lesions. Reticuloendothelial
Contrast Agents, as e.g.
superparamagnetic iron oxides (
SPIO), are taken up by healthy
liver tissue but not tumors.
These RES targeted
contrast agents provide a prolonged imaging window and enough time for high
spatial resolution or multiple
breath hold images. Reticuloendothelial
contrast agents have an increased sensitivity for the detection of small
liver lesions (e.g., metastases), compared with
gadolinium enhanced MRI and
spiral CT. At higher field strengths with an increased
signal to noise ratio the
susceptibility effect with iron oxide particles may be enhanced.
Other new agents (
Gadobenate Dimeglumine,
Gadoxetic Acid) have both an initial extracellular circulation and a delayed liver-specific uptake. Since a considerable part of these
contrast agents is excreted in the bile, functional biliary imaging can diagnose biliary anomalies, postoperative bile leaks, and anastomotic strictures. Other agents, such as
liposomes (with encapsulated
Gd-DTPA) or DOTA complexes are in different development stages.
See also
Hepatobiliary Contrast Agents,
Gadolinium Oxide,
Superparamagnetic Iron Oxide and
Liposomes.